Investor FAQs

CURE’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
Cure Pharmaceutical Corporation was founded in July 2011 and is a wholly-owned subsidiary of Cure Pharmaceutical Holding Corp, a public company.
CURE Pharmaceutical is listed on the OTC Market under the ticker symbol “CURR”.
CURE Pharmaceutical’s fiscal year ends on December 31.

Information on CURE’s management team can be found here.

Information on CURE’s Board of Directors can be found here.

You can view CURE’s corporate governance documents here.

SEC filings can be found here.

If you hold CURE stock in your own name (not through a broker) please contact CURE’s transfer agent:

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
Phone: (212) 828-8436
www.VStockTransfer.com

You can request a paper copy of your CURE Pharmaceutical stock certificate by contacting CURE’s transfer agent: VStock Transfer, LLC 18 Lafayette Place Woodmere, NY 11598 Phone: (212) 828-8436 www.VStockTransfer.com

You can sign up for email alerts to receive notification of announcements and upcoming events here.

Cure Pharmaceuticals’ CUSIP is: 23127P104

Key Contacts

Investor Relations

Gary Zwetchkenbaum
Plum Tree Consulting LLC
(516) 455-7662
[email protected]

Ina McGuinness
McGuinness Communications
(805) 427-1372
[email protected]

Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
www.vstocktransfer.com

Auditors

RBSM, LLP
805 3rd Avenue #1430
New York, NY 10022

Corporate Counsel

K&L Gates
10100 Santa Monica Blvd., 8th Fl.
Los Angeles, CA 90067